ETF - CNBC

search results for

refine results

sort by

Date
Relevance

result type

Articles
Video

Wires
Press Releases

Santoli: Steam coming out of markets below the surface

Discussing the markets with CNBC's Mike Santoli; Tom Lydon, ETF Trends; and Dave Wright, Sierra Funds.

Source: CNBC.com

Options Action: Bet on homebuilders?

Breaking down a bullish bet on the iShares U.S. Home Construction ETF (ITB) with CNBC contributor Mike Khouw.

Source: CNBC.com

'Bond king' Jeff Gundlach's is betting big on the mortgage market

DoubleLine’s Jeff Gundlach likes to talk on TV about the Fed and interest rates. Here’s what his bond ETF is actually investing in.

Source: CNBC.com

Bank stocks on pace for worst day since June as markets doubt Trump pro-growth policies

The SPDR S&P Bank ETF (KBE) and SPDR S&P Regional Bank ETF (KRE) were down about 4 percent intraday Tuesday.

Source: CNBC.com

Have investors fully priced in the Brexit scenario?

James Butterfill, head of research & investment strategy at ETF Securities, says he’s beginning to see “a floor in fund-flows data”, when commenting on Brexit and currencies.

Source: CNBC.com

A close look at close oil sentiment

Larry McDonald of ACG Analytics and Jake Weinig of Malachite Capital discuss options trades on the XOP ETF with Brian Sullivan.

Source: CNBC.com

Options Action: Trouble ahead for China?

"Fast Money" trader Dan Nathan breaks down a bearish bet on the iShares China Large-Cap ETF (FXI) in the options pit.

Source: CNBC.com

Final Trade: ORCL, EEM & more

The "Fast Money" traders share their final trades of the day including Oracle, iShares MSCI Emerging Markets ETF (EEM) and more.

Source: CNBC.com

Options Action: Time to take profits in tech?

Breaking down a bearish bet on the PowerShares QQQ ETF in the options pit with CNBC contributor Mike Khouw.

Source: CNBC.com

Pharma stocks: Big isn't always better

Large companies have gotten carried away with price increases and financial engineering, making smaller names more attractive, says Brad Loncar of the Loncar Cancer Immunotherapy ETF.

Source: CNBC.com